Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
SEQENS logo — Our science for your future

SEQENS

Our science for your future

Founded 2003 France France 1291 employees Private Equity Biotechnology, Pharmaceutical

General Information

Company Name SEQENS
Founded Year 2003
Location France France
Employees 1291
Industries Biotechnology, Pharmaceutical
Funding Stage Private Equity
Business Model B2B
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with SEQENS. To contact SEQENS, visit seqens.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SEQENS compare?

A PDF of SEQENS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SEQENS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SEQENS

SEQENS positions itself as a global leader in pharmaceutical solutions and specialty ingredients, reflected in its slogan, "Our science for your future." Founded in 2003 and based in France, the company operates 16 manufacturing plants and 9 R&D centers across Europe, North America, and Asia. With a workforce of 3,300, including 350 scientists and experts, SEQENS is committed to delivering customized solutions for its clientele.

The company boasts a diverse portfolio that includes active ingredients, pharmaceutical intermediates, and specialty ingredients. It excels at developing complex molecules by leveraging cutting-edge technologies and innovative approaches. SEQENS reported a revenue of 1 MM€, highlighting its robust market presence.

The last noted investment was a Private Equity Round on 22 June 2016, led by Mérieux Equity Partners. As a key player in the Biotechnology and Pharmaceutical industries, SEQENS offers potential investors a well-established foothold in a high-demand sector.

Business keywords: Pharmaceutical Solutions, Specialty Ingredients, Active Ingredients, Pharmaceutical Intermediates, Pharmaceutical Synthesis, R&D Centers, CDMO (Contract Development and Manufacturing Organization), CRDO (Contract Research and Development Organization), Generics, Innovative Pharmaceuticals, Custom Specialties, Cosmetics, Industrialization of Molecules, Personal Care, Technology Innovation

Services & Products

Manufacture of pharmaceutical ingredients
Development of custom specialties and chemical products
Research and development across multiple scientific disciplines
Support for personal care market with specialized ingredients
Innovation-driven solutions for health and specialty sectors

Target Customers

Pharmaceutical Companies Personal Care Brands Healthcare Sector Biotechnology Firms Specialty Chemical Companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round Undisclosed 1
Mérieux Equity Partners
Mérieux Equity Partners
22 Jun 2016
Seed Round Undisclosed 1
Eurazeo
01 Mar 2016

SEQENS Alternatives & Competitors

View All Alternatives
SEQENS vs
Avra Laboratories Pvt Ltd
Avra Laboratories Pvt Ltd India

Custom Synthesis from Idea to Market

210 employees
Biotechnology, Health Care
SEQENS vs
Bellen Chemistry Co., Ltd.
Bellen Chemistry Co., Ltd. China

Strive to be your first choice of a chemistry service provider based on specialized and innovative s...

Series C
23 employees
Biotechnology, Pharmaceutical
SEQENS vs
Anthem Biosciences Private Limited
Anthem Biosciences Private Limited India

Contract Research Organization / Contract Develop Manufacturing Organization (CRO/CDMO)

2040 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About SEQENS

Our science for your future
SEQENS was founded in 2003.
SEQENS is headquartered in France.
SEQENS operates in Biotechnology and Pharmaceutical. Its work centres on Pharmaceutical Solutions, Specialty Ingredients, Active Ingredients and Pharmaceutical Intermediates. Its customers include Pharmaceutical Companies, Personal Care Brands and Healthcare Sector.
SEQENS has a B2B business model. Its revenue comes from Product Sales, Service Fee and Licensing.
SEQENS has approximately 1291 employees.
SEQENS has completed 2 funding rounds. The latest funding stage is Private Equity.
SEQENS offers: Manufacture of pharmaceutical ingredients, Development of custom specialties and chemical products, Research and development across multiple scientific disciplines, Support for personal care market with specialized ingredients, Innovation-driven solutions for health and specialty sectors.
Top alternatives and competitors to SEQENS include Avra Laboratories Pvt Ltd, Bellen Chemistry Co., Ltd., Anthem Biosciences Private Limited, Shanghai Eyougene Biotechnology Development Co., Ltd. , Unither Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SEQENS and Avra Laboratories Pvt Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SEQENS, https://bouncewatch.com/company/seqens, updated 23 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout